Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health, Inc. director Andrea G. Perez Garcia reported a stock sale in a Form 4 filing. On 12/09/2025, the reporting person sold 2,500 shares of Class A common stock of Hims & Hers Health, Inc. at a price of $39.17 per share, in a transaction coded "S" for sale.
After this transaction, the reporting person beneficially owns 80,166 shares of Hims & Hers Health, Inc. Class A common stock in direct ownership. The filing notes that it was submitted as a Form 4 for one reporting person who serves as a director of the company.
An affiliate of HIMS has filed a notice of proposed sale of restricted securities under Rule 144. The filing covers the planned sale of 2,500 Class A shares through Fidelity Brokerage Services LLC on or about 12/09/2025, on the NYSE, with an indicated aggregate market value of $97,925.00. The Class A shares were originally acquired from the issuer on 03/15/2022 via restricted stock vesting as compensation. The table notes that 219,270,891 Class A shares were outstanding at the time referenced, and the seller represents that they are not aware of undisclosed material adverse information about the issuer.
Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum, a director and more than 10% owner, reported changes in his Class A common stock holdings dated 11/28/2025. The filing shows internal transfers among his direct ownership and various family trusts, including a transfer of 712,500 shares from the Andrew Dudum 2015 Trust to his direct holdings and an annuity payment-in-kind of 115,996 shares from the AD 2022 GRAT 3 to that trust.
The report also discloses a gift of 1,078,549 shares from the AD 2022 GRAT 3 to the Dudum Legacy 2021 Trust, recorded at a price of $0 with transaction code "G" (gift). After these movements, Dudum continues to hold a significant stake in Hims & Hers through a combination of direct ownership and multiple family and GRAT trusts.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported an insider transaction involving the company’s Class A common stock. On 12/01/2025, he transferred 5,000 shares as a gift to a donor-advised fund, with no sale proceeds reported (price shown as $0).
After this charitable transfer, Chi beneficially owns 286,675 Class A shares. This total includes 236 shares acquired on November 20, 2025 under the Hims & Hers Health, Inc. 2020 Employee Stock Purchase Plan. The filing is made as a Form 4 for a single reporting person.
Hims & Hers Health (HIMS) insider trade reported: the company’s Chief Legal Officer, listed as an officer of the issuer, sold 2,631 shares of Class A common stock on 11/24/2025. The sale was reported at a price of $35.22 per share and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 28, 2024, which is designed to allow executives to sell shares according to a preset schedule. After this transaction, the reporting person directly beneficially owns 153,225 shares of Class A common stock.
Hims & Hers Health, Inc. (HIMS) CFO Oluyemi Okupe reported option exercises and a share sale. On 11/17/2025, the executive exercised stock options for 7,615 Class A common shares at $11.53 and 15,572 shares at $5.01, increasing direct holdings before any sale.
On the same date, 23,187 Class A common shares were sold at an average weighted price of $36.809 under a Rule 10b5-1 trading plan adopted on May 21, 2025. Following these transactions, the executive directly owns 70,232 Class A common shares and indirectly owns 7,853 shares through the Oluyemi Okupe Separate Property Trust dated 9‑1‑2021.
The report also shows remaining stock options: 7,615 options with an exercise price of $11.53 and 48,554 options outstanding after the exercise, and 15,572 options at $5.01 with 158,808 options remaining. These options vest over multi-year schedules based on continued service.
Hims & Hers Health, Inc. announced that its board has authorized a new share repurchase program allowing the company to buy back up to $250.0 million of its Class A common stock. The 2025 Share Repurchase Program runs through November 11, 2028 and allows purchases from time to time through open market transactions, privately negotiated deals, Rule 10b5-1 plans or other methods, and it may be suspended or discontinued at any time. The company also reported that from October 1, 2025 through November 7, 2025 it repurchased 1,334,572 shares for a total of $55.5 million, fully using the capacity of its prior $100.0 million repurchase program that began in July 2024.
Hims & Hers Health, Inc. announced that its board has authorized a new share repurchase program allowing the company to buy back up to $250.0 million of its Class A common stock. The 2025 Share Repurchase Program runs through November 11, 2028 and allows purchases from time to time through open market transactions, privately negotiated deals, Rule 10b5-1 plans or other methods, and it may be suspended or discontinued at any time. The company also reported that from October 1, 2025 through November 7, 2025 it repurchased 1,334,572 shares for a total of $55.5 million, fully using the capacity of its prior $100.0 million repurchase program that began in July 2024.
Hims & Hers Health (HIMS) reported an insider stock sale by its Chief Legal Officer. On 11/10/2025, the officer sold 2,637 shares of Class A common stock at $42.53 per share pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024.
Following the sale, the officer beneficially owns 155,856 shares, held directly. This filing reflects a pre‑scheduled transaction under the company’s insider trading compliance framework.
Hims & Hers Health (HIMS) CEO Andrew Dudum reported multiple insider movements of Class A shares among family trusts, with no cash consideration, for estate-planning purposes.
Key actions include gifts and trust-to-trust transfers: 262,423 shares were gifted on 11/07/2025 from AD 2021 GRAT 2 to the Dudum Legacy 2021 Trust; 1,049,692 shares moved on 11/10/2025 from AD 2021 GRAT to the Dudum Family 2021 Trust; and 1,954,379 shares were gifted on 11/12/2025 from AD 2023 GRAT to the Dudum Family 2021 Trust. The Dudum Legacy 2021 Trust also made a pro rata distribution of 260,000 shares.
Dudum reports indirect holdings across multiple vehicles (GRATs and family trusts). The filing also lists Class V Common Stock, convertible into an equal number of Class A shares upon certain events, with 8,377,623 underlying Class A shares held by the Andrew Dudum 2015 Trust.
Hims & Hers Health (HIMS) received a Form 144 notice for a planned sale of 2,637 Class A shares. The filing lists an aggregate market value of $112,151.61, an approximate sale date of 11/10/2025, and execution on the NYSE through Fidelity Brokerage Services LLC.
The seller, Soleil Boughton, acquired these shares via restricted stock vesting on 09/15/2025 as compensation. Shares outstanding were 219,270,891. In the prior three months, the filing shows multiple sales by the same person, including 2,572 shares on 08/11/2025 for $132,818.08 and 2,571 shares on 08/25/2025 for $114,486.63.